Wyeth
Wyeth is an American pharmaceutical and consumer-healthcare brand founded in 1864 and acquired by Pfizer in 2009.
Last updated October 14, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Wyeth is a historic American pharmaceutical and healthcare brand whose origins date to a drugstore and pharmaceutical business established by brothers John and Frank Wyeth in Philadelphia in 1864. The company developed from a regional medicines business into one of the largest pharmaceutical enterprises in the United States, operating under names including American Home Products and, later, Wyeth. Its activities covered prescription medicines, vaccines, biotechnology, consumer healthcare, nutrition and animal-health products. The company’s early identity was built around pharmaceutical manufacturing and branded medicines. During the twentieth century it expanded through research, product development and acquisitions, gradually broadening its presence beyond traditional medicines. The company became particularly visible in consumer health through products such as Advil pain relievers, Centrum vitamins, Caltrate supplements, Robitussin cough medicines and ChapStick lip balm. Its nutrition business was anchored by infant-formula and pediatric-nutrition brands including Enfamil, while its prescription portfolio included medicines such as Premarin, Prempro, Effexor and Protonix at different points in its history. Wyeth adopted the name American Home Products Corporation in 1926 after a major corporate combination. American Home Products became a diversified healthcare group with pharmaceutical, consumer and agricultural interests. In 2002 the company changed its corporate name to Wyeth, reviving the historic identity associated with its pharmaceutical heritage. The rebranding was intended to present the company as a more focused research-based healthcare business rather than a collection of unrelated operating companies. A major turning point came in the 1990s and 2000s, when Wyeth increased its emphasis on prescription medicines, biologics, vaccines and biotechnology. Its purchase of American Cyanamid in 1994 added Lederle Laboratories and expanded the company’s pharmaceutical and agricultural operations. Wyeth later acquired biotechnology company Genetics Institute, strengthening its position in biologic medicines, including hemophilia treatments. It also developed or commercialized products in women’s health, neuroscience, gastroenterology, vaccines and specialty care. The company faced substantial legal, regulatory and reputational pressure during the 1990s and 2000s. Litigation relating to hormone-therapy products, including Prempro and Premarin, became a significant issue after studies raised concerns about risks associated with hormone replacement therapy. Wyeth also dealt with product-liability cases and regulatory scrutiny involving other products. These challenges occurred alongside pressure from patent expirations, rising research costs and increasing competition from generic and biotechnology companies. In January 2009 Pfizer announced an agreement to acquire Wyeth. The transaction closed later that year after shareholder and regulatory approval, creating one of the world’s largest pharmaceutical companies. Wyeth ceased to exist as an independent publicly traded corporation, while selected Wyeth names and product brands continued within Pfizer’s pharmaceutical, vaccine, nutrition and consumer-healthcare operations. Pfizer subsequently divested much of its consumer-healthcare business, including brands that had previously been associated with Wyeth, but the Wyeth name has continued to appear in certain nutrition and pharmaceutical contexts, especially through regional corporate and manufacturing entities. Today, Wyeth is best understood as a legacy healthcare brand and former independent pharmaceutical company within Pfizer’s historical portfolio. Its enduring brand associations include infant nutrition, vaccines, prescription medicines and established consumer-health products. The precise use of the Wyeth name varies by market and product category, and some former Wyeth brands are now owned or marketed by other c…
History
Wyeth traces its origins to 1864, when brothers John and Frank Wyeth established a drugstore and pharmaceutical business in Philadelphia. The enterprise initially operated in the tradition of nineteenth-century American pharmacy, combining the preparation and sale of medicines with efforts to standardize and manufacture pharmaceutical products. Over time, the business expanded beyond its local origins and became part of the consolidation of the American pharmaceutical industry. The company adopted the name American Home Products Corporation in 1926 following a corporate combination. Under that identity it built a broad healthcare portfolio through internal development and acquisitions. American Home Products operated across prescription drugs, consumer medicines, household healthcare, agricultural products and other related activities. Its growth reflected the rise of branded pharmaceuticals and mass-market healthcare products in the United States during the twentieth century. A significant expansion occurred in 1994 when American Home Products acquired American Cyanamid. The transaction brought Lederle Laboratories into the group and increased the company’s capabilities in prescription medicines, vaccines and other healthcare fields. American Home Products also expanded its biotechnology activities, including through the acquisition of Genetics Institute. This helped establish a stronger position in biologic therapies and specialty medicines, alongside its existing consumer and pharmaceutical businesses. The company’s portfolio became associated with several major healthcare categories. In prescription medicine, products included hormone therapies such as Premarin and Prempro, the antidepressant Effexor and the gastrointestinal medicine Protonix. In nutrition, Enfamil became a prominent infant-formula and pediatric-nutrition brand. In consumer healthcare, the group was associated at different times with Advil, Centrum, Caltrate, Robitussin and ChapStick. Product ownership and marketing arrangements later changed as a result of the Pfizer acquisition and subsequent divestitures. In 2002 American Home Products changed its corporate name to Wyeth. The change sought to unify the company under a historically recognizable pharmaceutical identity and to communicate a more focused healthcare strategy. Wyeth continued to invest in prescription medicines, vaccines, biotechnology and nutrition while managing the commercial and legal consequences of a large diversified product portfolio. The company encountered major challenges in the 2000s. Hormone-replacement therapy products became the subject of medical debate and litigation after the Women’s Health Initiative reported risks associated with certain hormone-therapy regimens. Wyeth also faced the normal pressures of the pharmaceutical industry, including patent expiry, generic competition, costly clinical development and regulatory requirements. These pressures contributed to a strategic environment in which scale and diversification were increasingly important. In January 2009 Pfizer agreed to acquire Wyeth. The transaction closed in October 2009, and Wyeth became part of Pfizer. The combination expanded Pfizer’s operations in vaccines, biologics, nutrition and consumer healthcare while also giving Pfizer access to Wyeth’s research and commercial infrastructure. Wyeth was no longer an independent listed company, but its name and selected product identities continued within Pfizer and, in some markets, through later owners of divested brands. The modern significance of Wyeth therefore has two dimensions. Historically, it represents a major American pharmaceutical company that evolved from a nineteenth-century pharmacy into a global healthcare group. Commercially, it remains a legacy brand associated with products and businesses that survived the acquisition under different ownership and organizational structures. The Wyeth name is still encountered in parts of the pharmaceutical and nutrition industries, although its use is not uniform across countries or product lines.
- 2009
Pfizer acquisition announced and completed
[3]Pfizer announced and completed its acquisition of Wyeth, ending Wyeth’s independent corporate existence.
- 2002
Corporate name changes to Wyeth
[1]American Home Products changed its corporate name to Wyeth and emphasized a more unified healthcare identity.
- 1994
American Cyanamid acquisition
[5]American Home Products acquired American Cyanamid, including Lederle Laboratories, broadening its pharmaceutical and healthcare operations.
- 1926
Company adopts the American Home Products name
[1]A corporate combination led the business to operate under the American Home Products Corporation name.
- 1864
Wyeth brothers establish the original business
[1]John and Frank Wyeth established the pharmaceutical business that later developed into Wyeth.
Products and positioning
A research-oriented healthcare company with major historical positions in prescription medicines, vaccines, biotechnology, infant nutrition and consumer healthcare.
Infant and pediatric nutrition
Enfamil
Enfamil is Wyeth’s best-known nutrition franchise, consisting of infant formulas and related pediatric-nutrition products. The line became a major part of Wyeth’s commercial identity and continued under Pfizer’s nutrition business after the acquisition.
Prescription hormone therapy
Premarin
Premarin is an estrogen-based prescription therapy historically commercialized by Wyeth. It was a major women’s-health product and later became closely associated with debate and litigation concerning the risks and appropriate use of menopausal hormone therapy.
Prescription hormone therapy
Prempro
Prempro combines estrogen and progestin for specified hormone-therapy uses. It was an important Wyeth product but became a focus of regulatory discussion and product-liability litigation following findings from the Women’s Health Initiative.
Prescription antidepressant
Effexor
Effexor, known generically as venlafaxine, was a major prescription neuroscience product associated with Wyeth. It helped make the company a significant participant in the antidepressant market before generic competition increased after patent protection ended.
Prescription gastrointestinal medicine
Protonix
Protonix is a proton-pump inhibitor used for acid-related gastrointestinal conditions. It was part of Wyeth’s prescription portfolio and later continued within Pfizer’s broader medicines business before facing generic competition.
Over-the-counter pain relief
Advil
Advil is an ibuprofen-based consumer pain-relief brand that was associated with Wyeth’s consumer-healthcare portfolio. Pfizer later sold its global consumer-healthcare business, so ownership and marketing arrangements for the brand changed after the Wyeth era.
Vitamins and dietary supplements
Centrum
Centrum is a multivitamin and dietary-supplement franchise that became part of Wyeth’s consumer-healthcare activities. It was later transferred through Pfizer’s consumer-healthcare transactions and is no longer a core Wyeth-controlled asset.
Calcium supplements
Caltrate
Caltrate is a calcium and bone-health supplement brand historically included in Wyeth’s consumer-healthcare portfolio. Its later ownership followed the divestiture of Pfizer’s consumer-healthcare business.
Controversies
2002
Hormone-therapy safety controversy
Wyeth’s Premarin and Prempro hormone-therapy products became subject to heightened medical, regulatory and legal scrutiny after Women’s Health Initiative findings identified important risks associated with certain hormone-therapy regimens. The controversy affected prescribing practices, public perception and subsequent product-liability litigation.
Brand decisions
2009
Pfizer acquires WyethM&ABackground
Both companies faced the scale requirements, research costs and portfolio pressures of the modern pharmaceutical industry.
Action taken
Pfizer agreed to acquire Wyeth and completed the transaction after shareholder and regulatory approval.
Aftermath
Wyeth became part of Pfizer, expanding Pfizer’s presence in vaccines, biologics, nutrition and consumer healthcare while ending Wyeth’s independent listing.
Announced transaction value. (2009)
2002
Rebrand from American Home Products to WyethStrategyBackground
The diversified American Home Products organization sought a more unified identity associated with its pharmaceutical heritage and healthcare focus.
Action taken
The company adopted Wyeth as its corporate name and used the identity across its principal healthcare businesses.
Aftermath
The rebrand preceded a period of increased emphasis on prescription medicines, vaccines, biotechnology and nutrition, before the company was acquired by Pfizer.
Recent events
- 2009
Pfizer to acquire Wyeth[2]
M&A
Pfizer announced an agreement to acquire Wyeth, combining two major pharmaceutical companies and expanding Pfizer’s presence in biologics, vaccines, consumer healthcare and nutrition.
- 2009
Pfizer completes acquisition of Wyeth[3]
M&A
The acquisition was completed after the required shareholder and regulatory processes, ending Wyeth’s existence as an independent public company.
Sources5 sources
Cite this profile: Cite the canonical profile. /brand-wiki/惠氏 · Editorial policy · How profiles are compiled